SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE
SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE
Certificado de depósito · US82686Q1013 · SLN · A2QB4J (XNAS)
Resumen
5,17 USD
-2,08 % -0,11 USD
NASDAQ (XNAS) · Precios actuales y gráficos en MoneyPeak
10.06.2025 19:59

Cotizaciones actuales de SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
SLN
USD
10.06.2025 19:59
5,17 USD
5,28 USD
-2,08 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
-2,08 % -8,98 % 39,73 % 7,71 % -35,29 % -74,76 % -73,49 %

Perfil de la empresa para SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE Certificado de depósito

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Datos de la empresa

Nombre SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE
Empresa Silence Therapeutics plc
Símbolo SLN
Sitio web https://www.silence-therapeutics.com
Mercado principal XNAS NASDAQ
WKN A2QB4J
ISIN US82686Q1013
Tipo de valor Certificado de depósito
Sector Healthcare
Industria Biotechnology
CEO Mr. Craig A. Tooman M.B.A.
Capitalización de mercado 149 Mio
País Reino Unido
Moneda USD
Empleados 0,1 T
Dirección 72 Hammersmith Road, W14 8TH London
Fecha de OPV 2020-09-08

Símbolos de cotización

Nombre Símbolo
Frankfurt XRP2.F
NASDAQ SLN

Otras acciones

Los inversores que tienen SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE también tienen las siguientes acciones en su cartera:
LONDON SECURITY PLC - ORD 1P
LONDON SECURITY PLC - ORD 1P Acción
WTS LKD ORD A SHS YANGZHOU 27/01/24
WTS LKD ORD A SHS YANGZHOU 27/01/24 Verbriefte Derivate
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025